For B-cell lymphoma, a combination of CD47 antagonistic antibody with the standard-of-care CD20 antibody rituximab (RTX) yielded complete responses in relapsed and refractory patients [9]. The gene discussed is CD47; the disease is B-cell non-Hodgkin lymphoma.